Get the Stockscreener App
4.42
2.08%
0.09
After Hours:
4.42
Abeona Therapeutics Inc stock is traded at $4.42, with a volume of 1.19M.
It is up +2.08% in the last 24 hours and down -16.60% over the past month.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
See More
Previous Close:
$4.33
Open:
$4.35
24h Volume:
1.19M
Relative Volume:
0.97
Market Cap:
$252.16M
Revenue:
$5.82M
Net Income/Loss:
$71.18M
P/E Ratio:
4.4324
EPS:
0.9972
Net Cash Flow:
$-84.30M
1W Performance:
-2.86%
1M Performance:
-16.60%
6M Performance:
-17.54%
1Y Performance:
-11.60%
1-Day Range:
$4.35
$4.52
1-Week Range:
$4.285
$4.625
52-Week Range:
$3.9328
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
4.42 | 247.02M | 5.82M | 71.18M | -84.30M | 0.9972 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Meme Stocks: Does Abeona Therapeutics Inc have strong EBITDA margins2026 Earnings Surprises & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2025 earnings call transcript - MSN
HC Wainwright Issues Pessimistic Outlook for ABEO Earnings - MarketBeat
Abeona Therapeutics Adopts Third Amended and Restated Bylaws Effective March 16, 2026 - Minichart
Form 8K Abeona Therapeutics Inc For: 20 March By Investing.com - Investing.com Australia
Form 8K Abeona Therapeutics Inc For: 20 March - Investing.com
Abeona Therapeutics Tightens Shareholder Meeting and Governance Rules - TipRanks
Abeona (NASDAQ: ABEO) tightens bylaws on meetings and director nominations - Stock Titan
Abeona Therapeutics Earnings Notes - Trefis
Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB - Seeking Alpha
HC Wainwright & Co. Reiterates Buy Rating for Abeona Therapeutics (ABEO) | ABEO Stock News - GuruFocus
Abeona Therapeutics (NASDAQ:ABEO) Earns Buy Rating from HC Wainwright - MarketBeat
Abeona Therapeutics (ABEO) Receives a Buy from Oppenheimer - The Globe and Mail
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2025 Earnings Call Transcript - Insider Monkey
Abeona Therapeutics Balances Big Windfall With Slow Ramp - The Globe and Mail
Abeona Therapeutics: Early Zevaskyn Revenue Marks A Key Inflection Point (NASDAQ:ABEO) - Seeking Alpha
Abeona Therapeutics (ABEO) One Off US$152.4m Gain Tests Bullish Profitability Narrative - simplywall.st
Abeona targets activation of 7 QTCs for ZEVASKYN by end of 2026 as patient demand doubles - MSN
Stifel cuts Abeona Therapeutics stock price target on sales timing By Investing.com - Investing.com Australia
Oppenheimer reiterates Abeona Therapeutics stock rating at Outperform By Investing.com - Investing.com Canada
Stifel cuts Abeona Therapeutics stock price target on sales timing - Investing.com
Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: - GuruFocus
Abeona Therapeutics Reports 2025 Financial Results, ZEVASKYN Launch Momentum, and $191.4M Cash Position - Minichart
Abeona (ABEO) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
ABEO: Strong launch momentum, profitability, and expanding access position ZEVASKYN for growth - TradingView
Abeona (ABEO) Q4 2025 Earnings Call Transcript - The Globe and Mail
Abeona Therapeutics Q4 Earnings Call Highlights - MarketBeat
ABEO: 2025 marked a profitable year with ZEVASKYN's launch, expanding access, and robust financials - TradingView
Earnings call transcript: Abeona Therapeutics Q4 2025 shows revenue growth - Investing.com
Abeona Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Abeona Therapeutics 2025 Financial Results: Annual Profit and Q4 BeatNews and Statistics - IndexBox
Abeona Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Abeona Therapeutics (ABEO) Reports Mixed FY Results with Revenue Beat - GuruFocus
Abeona Therapeutics FY income from operations USD -89.448 million versus Ibes estimate USD -78.4 million - marketscreener.com
Abeona Therapeutics (NASDAQ:ABEO) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
ABEO Exceeds Revenue Expectations with Strong Biopsy and Treatme - GuruFocus
ABEONA THERAPEUTICS ($ABEO) Releases Q4 2025 Earnings - Quiver Quantitative
The latest financial data released by biotechnology company Abeona Therapeutics Inc shows its annual operating income recorded at -89.448 millions USD. - Bitget
Abeona Therapeutics: Fourth Quarter Earnings Overview - Bitget
Abeona Therapeutics 10-K: $5.82M Revenue, $71.18M Net Income - TradingView
Abeona Therapeutics: Q4 Earnings Snapshot - Barchart.com
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates - The Manila Times
Abeona (NASDAQ: ABEO) shifts to commercial stage with ZEVASKYN and $155M PRV cash - Stock Titan
Abeona Therapeutics (Nasdaq: ABEO) turns 2025 profit on PRV sale and builds cash - Stock Titan
First ZEVASKYN patients treated as Abeona banks $191M cash - Stock Titan
Earnings Scheduled For March 17, 2026 - Benzinga
Abeona Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Abeona Therapeutics CFO Vazzano sells $3.7k in stock By Investing.com - Investing.com Australia
Abeona Therapeutics CFO Vazzano sells $3.7k in stock - Investing.com
ABEO SEC FilingsAbeona Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Abeona Therapeutics FY 2025 earnings preview - MSN
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abeona Therapeutics Inc Stock (ABEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Vazzano Joseph Walter | Chief Financial Officer |
Mar 16 '26 |
Sale |
4.76 |
785 |
3,737 |
567,775 |
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):